Form 4: Repligen Corp COO Bylund Receives Stock Awards and Options
SEC Form 4 Filing
James Bylund, Chief Operating Officer of Repligen Corporation, was granted restricted stock units and stock options on February 27, 2024.
Summary
- James Bylund, the Chief Operating Officer of Repligen Corporation, received 8,691 restricted stock units on February 27, 2024.
- These restricted stock units represent a contingent right to receive one share of Repligen Corporation's common stock each.
- The restricted stock units vest in equal annual installments over a three-year period, starting on the first anniversary of the grant date.
- Bylund also received stock options for 8,632 shares with an exercise price of $192.71.
- One third of the stock options will vest and become exercisable annually on February 27, 2025, February 27, 2026 and February 27, 2027.
Sentiment
Score: 7
Explanation: The sentiment is neutral to positive. The granting of stock options and restricted stock units is a standard practice that aligns management's interests with shareholders. The vesting schedule promotes long-term commitment.
Positives
- The grant of restricted stock units and stock options aligns the executive's interests with those of the shareholders.
- The vesting schedule encourages long-term commitment from the COO.
Future Outlook
The vesting of the restricted stock units and stock options is contingent upon continued service with the company.
Industry Context
Stock options and restricted stock units are common forms of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders and incentivizing long-term value creation.
Comparison to Industry Standards
- Executive compensation packages in the biotech industry often include a mix of salary, bonus, stock options, and restricted stock units.
- The specific terms of these packages, such as vesting schedules and exercise prices, vary depending on the company's size, performance, and industry benchmarks.
- Comparing Repligen's executive compensation practices to those of its peers, such as Danaher, Thermo Fisher Scientific, and Sartorius, would provide a more comprehensive assessment.
Stakeholder Impact
- Shareholders: The grants align management's interests with shareholder value creation.
- Employees: The grants may have a positive impact on employee morale by demonstrating the company's commitment to its leadership team.
Key Dates
| Date | Description |
|---|---|
| 02/27/2024 | Date of the transaction: Bylund was awarded restricted stock units and stock options. |
| 02/27/2025 | First vesting date for one-third of the stock options. |
| 02/27/2026 | Second vesting date for one-third of the stock options. |
| 02/27/2027 | Third vesting date for one-third of the stock options. |
| 02/27/2034 | Expiration date of the stock options. |
| 02/29/2024 | Date of the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.